Title: Vical to Present at Scientific and Investor Conferences Date:
5/29/2007 6:30:00 AM
SAN DIEGO, May 29 /PRNewswire-FirstCall/ -- As previously announced, the Vical
Incorporated (Nasdaq: VICL) presentation at the Bank of America Health Care Conference on
May 30 at 3:20 p.m. Pacific Time (6:20 p.m. Eastern Time) will be available by live and
archived webcast through links on the events page at http://www.vical.com. The company's
presentations at the following series of upcoming conferences will not be webcast:
-- World Vaccine Congress Asia 2007 (Singapore, June 4 - 7).
Vijay B. Samant, the company's President and Chief Executive Officer
will present a status report on recent developments in DNA vaccines for
influenza in a pre-conference influenza vaccine summit chaired by
Jacques-Francois Martin, President of Parteurop, France. Highlights
will include the use of adjuvants such as the company's patented
Vaxfectin(TM) lipid-based compound, and a case study on the company's
pandemic influenza DNA vaccine program.
-- Friedman Billings Ramsey Growth Conference (New York, May 30 - 31).
-- The annual meeting of the American Society of Gene Therapy (Seattle,
May 30 - June 3).
-- The annual meeting of the American Society of Clinical Oncology
(Chicago, June 1 - 5).
-- Goldman Sachs Global Healthcare Conference (Dana Point, CA, June 12 -
15).
-- Needham & Company Biotechnology & Medical Technology Conference (New
York, June 13 - 14).
-- Piper Jaffray London Health Care Conference (London, June 20 - 21).
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA
delivery technologies for the prevention and treatment of serious or life-threatening
diseases. Potential applications of the company's DNA delivery technology include DNA
vaccines for infectious diseases or cancer, in which the expressed protein is an
immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system
stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic
growth factor. The company is developing certain infectious disease vaccines and cancer
therapeutics internally. In addition, the company collaborates with major pharmaceutical
companies and biotechnology companies that give it access to complementary technologies or
greater resources. These strategic partnerships provide the company with mutually
beneficial opportunities to expand its product pipeline and address significant unmet
medical needs. Additional information on Vical is available at http://www.vical.com.
This press release contains forward-looking statements subject to risks and
uncertainties that could cause actual results to differ materially from those projected.
Forward-looking statements include statements about the company's focus, collaborative
partners, product candidates, and developmental status. Risks and uncertainties include
whether any product candidates will be shown to be safe and efficacious in clinical
trials, the timing of clinical trials, whether Vical or its collaborative partners will
seek or gain approval to market any product candidates, the dependence of the company on
its collaborative partners, and additional risks set forth in the company's filings with
the Securities and Exchange Commission. These forward-looking statements represent the
company's judgment as of the date of this release. The company disclaims, however, any
intent or obligation to update these forward-looking statements.
Contacts: Investors: Media:
Alan R. Engbring Susan Neath
Vical Incorporated Porter Novelli Life Sciences
(858) 646-1127 (619) 849-6007
Website: http://www.vical.com
SOURCE Vical Incorporated
-0- 05/29/2007
/CONTACT: Investors, Alan R. Engbring of Vical Incorporated,
+1-858-646-1127; or Media, Susan Neath of Porter Novelli Life Sciences,
+1-619-849-6007/
/Web site: http://www.vical.com/
(VICL)
CO: Vical Incorporated; Bank of America; American Society of Clinical
Oncology; American Society of Gene Therapy; American Society of Clinical
Oncology; Goldman Sachs; Needham & Company; Piper Jaffray
ST: California, New York, Washington, Singapore, England
IN: MTC BIO HEA
SU: CCA
KS-WB
-- CLTU028 --
5074 05/29/2007 06:30 EDT http://www.prnewswire.com
|